Laureate Pharma, Inc. has entered into a biopharmaceutical development and manufacturing agreement with Bradmer Pharmaceuticals, Inc. for process development and cGMP manufacture of the monoclonal antibody precursor of Neuradiab, Bradmer’s candidate for treatment of brain cancer. The project is well underway and Laureate expects to supply Bradmer with product by the end of this year. Terms of the agreement were not disclosed. “We are excited to apply our experience and expertise...